Targeting drug delivery and the small airways in asthma.
This year will see the launch of the first chlorofluorocarbon (CFC)-free formulation of beclomethasone. Developed by 3M Health Care, its extrafine formulation gives significant benefits resulting from increased lung deposition and improved inhaler technology. Its difference from CFC-propelled inhalers is so marked that it will challenge views about about the risk-benefit profile of beclomethasone.